Pre-exposure Prophylactic (Preventive) Antibody Therapy - EVUSHELD

TO REGISTER FOR EVUSHELD ANTIBODY THERAPY CLICK THE BUTTON BELOW

OUR REGISTRATION FORM MAY BE HAVING TECHNICAL DIFFICULTIES – IF YOU ARE UNABLE TO REGISTER PLEASE CALL THE OFFICE AT 972-688-6330 AND SELECT OPTION 1

EVUSHELD is a combination of two long-acting monoclonal antibodies (LAAB) and is the only antibody therapy authorized in the U.S. for pre-exposure prophylactic (preventive) use against COVID-19 in immunocompromised patients. EVUSHELD therapy is administered in two quick intramuscular doses and provides up to a 77% reduction in the risk of COVID-19 infection for 6 months after administration.

You MUST meet the following criteria to be eligible for Evusheld treatment:

  • 12 years of age or older

  • Weigh at least 88 pounds (40 kg)

  • Not currently infected with SARS-CoV-2 and who have not had recent known close contact with someone who is infected with SARS-CoV-2

  • Have not received a COVID-19 vaccine within the last 2 weeks

  • Have moderate to severe immune compromise due to a medical condition or have received immunosuppressive medicines or treatments and may not mount an adequate immune response to COVID-19 vaccine

  • OR that any vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (such as severe allergic reaction) to a COVID-19 vaccine(s) or COVID- vaccine ingredient.

  • Providers – https://www.fda.gov/media/154701/download

  • Patients, Parents and Caregivers – https://www.fda.gov/media/154702/download

What is Evusheld?

EVUSHELD is a combination of two long-acting monoclonal antibodies (LAAB) and is the only antibody therapy authorized in the U.S. for pre-exposure prophylactic (preventive) use against COVID-19 in immunocompromised patients. EVUSHELD therapy is administered in two quick intramuscular doses and provides up to a 77% reduction in the risk of COVID-19 infection for 6 months after administration.

Eligibility Criteria

You MUST meet the following criteria to be eligible for Evusheld treatment:

  • 12 years of age or older

  • Weigh at least 88 pounds (40 kg)

  • Not currently infected with SARS-CoV-2 and who have not had recent known close contact with someone who is infected with SARS-CoV-2

  • Have not received a COVID-19 vaccine within the last 2 weeks

  • Have moderate to severe immune compromise due to a medical condition or have received immunosuppressive medicines or treatments and may not mount an adequate immune response to COVID-19 vaccine

  • OR that any vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (such as severe allergic reaction) to a COVID-19 vaccine(s) or COVID- vaccine ingredient.

FDA Evusheld Fact sheet

  • Providers – https://www.fda.gov/media/154701/download

  • Patients, Parents and Caregivers – https://www.fda.gov/media/154702/download

8:30am – 2:30pm
  • Thursday March 3rd: 5:30pm – 9:00pm
  • Saturday March 5th: 2:00pm – 5:30pm
  • Monday March 7th: 5:30pm – 9:00pm
  • Wednesday March 9th: 5:30pm – 9:00pm
  • Monday March 21st: 5:30pm – 9:00pm
  • Wednesday March 23rd: 4:30pm – 8:00pm
  • Tuesday March 29th: 4:30pm – 8:00pm
  • Friday April 8th: 5:30pm – 9:00pm
  • Sunday April 10th: Time TBD